http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer
-
Halozyme elects Jim Lang to board of directors
-
Jim Lang Elected to Halozyme's Board of Directors
-
German court grants HALOZYME injunction against Merck's Keytruda SC
-
Halozyme Wins Preliminary Injunction Against Merck's Keytruda SC in Germany
-
Halozyme to Participate in the 8th Annual Evercore Healthcare Conference
-
Halozyme completes $750 million Elektrofi acquisition
-
Halozyme Completes Acquisition of Elektrofi, Expanding Breadth of Offerings in Drug Delivery
-
Merus and Halozyme partner on subcutaneous petosemtamab formulation
-
Merus and Halozyme partner on subcutaneous petosemtamab formulation
-
Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab
-
FDA approves DARZALEX Faspro for high-risk smoldering multiple myeloma
-
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
-
HALOZYME RAISES 2025 FINANCIAL GUIDANCE AND REPORTS STRONG THIRD QUARTER 2025 FINANCIAL AND OPERATING RESULTS
-
Halozyme to Report Third Quarter 2025 Financial and Operating Results
-
NASDAQ: HALO Halozyme acquires Elektrofi for $750 million plus milestones
-
Halozyme to Acquire Elektrofi, Expanding Our Offerings in Innovative Drug Delivery and Strengthening Long-Term Growth into 2040s
-
Halozyme to Participate at Upcoming Investor Conferences
-
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG SECOND QUARTER 2025 RESULTS
-
European Commission approves Halozyme's DARZALEX Faspro for smouldering multiple myeloma
-
European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma
-
Halozyme to Report Second Quarter 2025 Financial and Operating Results
-
Halozyme Therapeutics (HALO) added to Russell 1000
-
Halozyme Therapeutics Added to Russell 1000® Index
-
Halozyme Therapeutics (HALO) Announces argenx Received European Commission Approval for VYVGART Subcutaneous Injection with ENHANZE
-
Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Halozyme to Participate at Upcoming Investor Conferences
-
Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb (BMY) Received European Commission Approval for Subcutaneous Opdivo Co-Formulated with ENHANZE
-
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
-
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
-
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
-
Halozyme to Report First Quarter 2025 Financial and Operating Results
-
Halozyme Therapeutics (HALO) Announces argenx Received Positive CHMP Opinion for VYVGART
-
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
-
Halozyme Therapeutics (HALO) Sues Merck (MRK) for Patent Infringement over Subcutaneous Keytruda Formulation
-
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
-
Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating
-
Halozyme Therapeutics (HALO) Announces EU Approval of Subcutaneous DARZALEX-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligi
-
European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
-
Halozyme Therapeutics (HALO) Announces EU Approval of Subcutaneous RYBREVANT
-
European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
-
Halozyme Therapeutics (HALO) Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo with ENHANZE
-
Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
-
Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference
-
HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS
-
Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
-
Halozyme Therapeutics (HALO): CHMP Issues Positive Opinion for Subcutaneous RYBREVANT Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated NSCLC
-
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT®(amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
-
Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance
-
Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance
